AUTHOR=Cao Xiao , Sun Mingyao , Yang QiuYu , Wang Qi , Hou Liangying , Wang Jing , Wu Yu , Ge Long 

TITLE=Risk of abnormal pregnancy outcomes after using ondansetron during pregnancy: A systematic review and meta-analysis

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.951072

DOI=10.3389/fphar.2022.951072

ISSN=1663-9812

ABSTRACT=<p><bold>Background:</bold> Hyperemesis gravidarum is a serious pregnancy complication that affects approximately 1% of pregnancies worldwide.</p><p><bold>Objective:</bold> To determine whether the use of ondansetron during pregnancy is associated with abnormal pregnancy outcomes.</p><p><bold>Search strategy:</bold> PubMed, Cochrane Library, CINAHL, Embase, CNKI, CBM, WANFANG, and <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> were searched for citations published in any language from inception to 15 December 2021.</p><p><bold>Selection criteria:</bold> Eligible studies included any observational study.</p><p><bold>Data collection and analysis:</bold> Odds ratio (OR) and 95% confidence interval (CI) were used as indicators to examine the association between ondansetron and abnormal pregnancy outcomes.</p><p><bold>Main results:</bold> Twenty articles from 1,558 citations were included. Our preliminary analysis showed that compared with the unexposed group, the use of ondansetron during pregnancy may be associated with an increased incidence of cardiac defects (OR = 1.06, 95% CI: 1.01–1.10), neural tube defects (OR = 1.12, 95% CI: 1.05–1.18), and chest cleft (OR = 1.21, 95% CI: 1.07–1.37). Further sensitivity analysis showed no significant association between ondansetron and cardiac defects (OR = 1.15,95% CI: 0.94–1.40) or neural tube defects (OR = 0.87,95% CI: 0.46–1.66). When controversial studies were eliminated, the results for the chest defects disappeared. Simultaneously, we found that the use of ondansetron was associated with a reduced incidence of miscarriage (OR = 0.53, 95% CI: 0.31–0.89). Ondansetron was not associated with orofacial clefts (OR = 1.09,95% CI: 0.95–1.25), spinal limb defects (OR = 1.14,95% CI: 0.89–1.46), urinary tract deformities (OR = 1.06,95% CI: 0.97–1.15), any congenital malformations (OR = 1.03,95% CI: 0.98–1.09), stillbirth (OR = 0.97,95% CI: 0.83–1.15), preterm birth (OR = 1.22,95% CI: 0.80–1.85), neonatal asphyxia (OR = 1.05,95% CI: 0.72–1.54), or neonatal development (OR = 1.18,95% CI: 0.96–1.44) in our primary analysis.</p><p><bold>Conclusion:</bold> In our analysis, using ondansetron during pregnancy was not associated with abnormal pregnancy outcomes. Although our study did not find sufficient evidence of ondansetron and adverse pregnancy outcomes, future studies including the exposure period and dose of ondansetron, as well as controlling for disease status, may be useful to truly elucidate the potential risks and benefits of ondansetron.</p>